<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ ABDX.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">ABDX.L</div>
            <div class="company-name">Abingdon Health Plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£16,320,060</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 1127 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ WATCH</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">49</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">40</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fef3c7; color: #92400e;">EARLY BUILD</span>
            </div>
            
            <div class="thesis-line">
                WATCH - EARLY_BUILD timing with 49/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%); border: 2px solid #f59e0b;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üè≠</span>
                CrashDash Intelligence ‚Ä¢ Industrials
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#f59e0b 223.20000000000002deg, #e5e7eb 223.20000000000002deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #f59e0b;">62</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #f59e0b; margin-bottom: 12px;">HIGH PANIC</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üü† Fear dominant - watch for reversal signs</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 40/40</div>
                            <div>üìâ Volume: 6/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 10/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #f59e0b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üü† Fear 62/100</span><span style="display: inline-block; background: #10b981; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üìä Building</span>
                </div>
                
                <!-- Opportunity Flag -->
                <div style="margin-top: 20px; padding: 16px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 10px; color: white; font-weight: 700; font-size: 16px;">üéØ ‚ö†Ô∏è HIGH PANIC + Early timing = Potential accumulation phase</div>
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 93.60000000000001deg, #e5e7eb 93.60000000000001deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">26</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">‚ö™ LOW COMPRESSION (Early/Weak)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.2</strong> signals/week</div>
                                <div><strong>2</strong> RSI &lt; 20 events</div>
                                <div><strong>1</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+300%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">11/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 27.500000000000004%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.2 signals/week | 2 RSI<20 | 1 escalations | üéØ MILD COMPRESSION</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Normal volume</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #f59e0b;">10/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #f59e0b; height: 100%; width: 66.66666666666666%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">SOLID MOVER - Historical 3x+ (300%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üíî Price destruction: 40/40 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üìà Historical upside: 300% proven capacity</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    ‚öñÔ∏è Mixed signals - Fear and facts balanced, wait for clarity
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Industrials)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book decline or cancellations</div><div>‚Ä¢ Margin compression (input costs)</div><div>‚Ä¢ Cyclical demand weakness</div>
                    </div>
                    
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book growth or new contracts</div><div>‚Ä¢ Margin recovery (efficiency gains)</div><div>‚Ä¢ Cyclical upturn (capex recovery)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Final Results</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Launch of seaweed-based lateral flow housings</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Trading update</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Notice of Results</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Holding(s) in Company</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #f59e0b;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #f59e0b; font-size: 20px;">WATCH</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    ‚è≥ Monitor for timing regime change or panic escalation
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (4/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üî¥</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">62/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚úÖ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">EARLY_BUILD</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ö†Ô∏è</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">49/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üéØ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">40/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üè≠</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">0 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 49/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: EARLY_BUILD</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 1 rallies, 300% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 40/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 9/20 ‚Ä¢ Score: 11/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 89.3% from peak ‚Ä¢ Score: 18/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Normal volume</strong><br><small>1.4x average ‚Ä¢ Score: 3/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>1 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Major upside</strong><br><small>Historical best: +300% ‚Ä¢ Score: 12/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">72%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">300%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">0.2x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Early stage positioning offers best R:R if catalysts appear</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">timing=EARLY BUILD ‚Ä¢ current return=71.9%</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical ‚Ä¢ signal date=2022-12-16</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Watch / Starter</div>
                    <div style="font-size: 14px; opacity: 0.9;">Wait for base + catalyst confirmation; starter position only</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0-1% until CONFIRMED</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Invalidation = breaks recent lows / dilution / suspension</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out 25% at +15%, 25% at +50%, runner above</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 49/100 APEX score. Historical data shows 1 rallies averaging 300% upside. Current position: +71.9%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Early regime often offers best risk/reward</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Early accumulation phase. Watch for confirmation before committing size.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 40/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìà</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Final Results</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 85/100 ‚Ä¢ BULLISH</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    FINANCIAL RESULTS: Revenue ¬£6.1m | 49% growth | ‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">8th Oct 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #10b981;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #10b981;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">85/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">FINANCIAL RESULTS: Revenue ¬£6.1m | 49% growth</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">üü¢ LOW RISK: Positive signals, minimal concerns</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìä ANALYZE: Determine offer price, arbitrage opportunity if discount</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚ö†Ô∏è CRITICAL: Serious company health concerns - potential distress signal</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Our Audit</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">52%, 49%, 55%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
8 Oct 2024 07:00
RNS Number : 2640H
Abingdon Health PLC
08 October 2024
Abingdon Health plc
("Abingdon" or "the Company")
Final Results
York, U.K. 8 October 2024:
Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces its final results for the year ended 30 June 2024.
Financial highlights
¬∑
Revenue growth of 52% to ¬£6.1m (2023: ¬£4.0m) -
49% growth when excluding acquisitions.
¬∑
H2 FY 2024 showed revenue growth of 55% compared to H1 FY 2024
.
¬∑
Adjusted* EBITDA losses reduced significantly to ¬£1.1m (2023: ¬£2.9m loss).
¬∑
Gross margin of 60% (2023: 51%).
¬∑
Cash as at 30 June 2024: ¬£1.4m (2023: ¬£3.2m) -
with additional net proceeds of ¬£5.1m raised post-year end
*
Earnings before interest, tax, depreciation, amortisation and one-off costs as outlined above, is a non-GAAP measure used by management and is not an IFRS disclosure.
Operational highlights (including post-period end)
¬∑
51% year-on-year revenue growth in CRO/CDMO business due to an increase in customers utilising Abingdon's contract development, scale-up, technical transfer and manufacturing services; as well as an expansion in the Company's range of services such as regulatory support.
¬∑
Three customer products transitioned into manufacturing in FY24:
o
Salignostics (saliva pregnancy test),
o
LoopDX (sepsis),
o
Up Front Diagnostics (stroke).
¬∑
Product business revenues up 56% year-on-year - benefitting from the launch of three lateral flow tests with Boots.
¬∑
Continued expansion of product range and sales and distribution platform expected in FY25 to generate further product sales growth.
¬∑
Acquisition of
IVDeology for a maximum consideration of ¬£0.7m in shares completed in May 2024 strengthens existing regulatory service offering.
¬∑
New US commercial office and R&D laboratory targeted for Q4 of calendar year 2024.
¬∑
Acquisition of Compliance Solutions (Life Sciences) for a maximum consideration of ¬£3.2m in cash and shares completed in August 2024 also increases breadth of international regulatory service offering.
¬∑
¬£5.6m (gross) fundraise completed in August 2024 to be used to invest in product development, analytical laboratory service expansion and for working capital.
Chris Yates, Chief Executive Officer of Abingdon Health, said:
"
As a CRO/CDMO focused on lateral flow technology with a well-established track record of bringing products from 'idea to market' we believe we are well-placed to support a broad range of customers. The recent acquisitions of IVDeology and Compliance Solutions (Life Sciences), and the further investment in expanding our analytical laboratory service mean that we can now offer more a comprehensive service.
"Our key financial priorities are to grow our revenues and reduce our cashburn through continued close cost management, therefore
moving the Company to a positive cashflow position, having achieved a cashflow positive quarter in Q4-FY2024
.
We are confident that our contract services customer base and our current growing pipeline means we are well positioned to grow our business and deliver shareholder value going forward."
Enquiries:
Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Yates,
Chief Executive Officer
Via Walbrook PR
Chris Hand,¬†Non-
Executive Chairman
Zeus Capital (Sole Broker and Nominated Adviser)
Tel:
+44 (0) 20 7220 1666
Chris Fielding / Isaac Hooper/Alex Campbell-Harris¬†(Corporate Finance)
Fraser Marshall (Corporate Broking)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or
abingdon@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
Phillip Marriage
+44 (0)7867 984 082
The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.
About Abingdon Health plc
Abingdon Health¬†Group is a leading med-tech contract service provider offering its services to an international customer base.
The Company's
CDMO division
offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.¬†Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
Abingdon's regulatory services companies,
Compliance Solutions (Life Sciences)
and
IVDeology
, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.
Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The
Abingdon Simply Test
e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008,¬†Abingdon Health¬†is headquartered in¬†York, England.
For more information visit:
www.abingdonhealth.com
Chairman & CEO Joint Statement
We are pleased to report continued revenue growth in the year ended 30 June 2024 and an improving cashflow and EBITDA performance, particularly in the second half of the financial year. Revenue increased by 52% to ¬£6.1m (2023: ¬£4.0m) and Adjusted EBITDA losses reduced to ¬£1.1m from ¬£2.9m in FY23.
As well as increasing our revenue in the year, we also completed two acquisitions (one post year-end) that will enhance our regulatory service capability. We successfully raised ¬£5.6m post year-end to support expansion of the analytical laboratory services at our Doncaster site, enhance product development, and provide additional working capital.
Our service proposition is resonating well with our international customer base, and we believe we are well placed for continued revenue growth. The lateral flow market continues to grow, and we are seeing expanding use of the technology across a range of applications. As a knowledge leader in the application of lateral flow technology Abingdon is proud to support its customers in bringing innovative rapid testing products through development and onto the market.
Abingdon's mission is improving life through making rapid tests accessible to all; and we seek to fulfil this by supporting our customers in bringing their innovative lateral flow products to market. We are seeing growth in the market and Abingdon is active across a broad range of applications including clinical (point of care and self-test), animal health, plant pathogen, food and environmental testing.
Our customer service proposition is to provide all the "pieces of the jigsaw" to allow a customer to take a project from idea through to commercial success. Abingdon's service offering includes contract research and development, scale-up, technical transfer, manufacturing, packaging design and kitting, regulatory support, and analytical laboratory services. Abingdon's integrated Contract Research Organisation ("CRO") and Contract Development and Manufacturing Organisation ("CDMO") model continues to resonate well with a diverse customer base and we have broadened and deepened our service offering in the year and post-year-end through the acquisition of regulatory service providers IVDeology, in May 2024, and Compliance Solutions (Life Sciences), in August 2024. Furthermore, we will invest to expand our analytical laboratory service offering following the fundraising completed in August 2024 which raised gross proceeds of ¬£5.6m.
The rapid diagnostic market is forecast to be worth over $280 billion by 2033 growing at a cumulative annual growth rate (CAGR) of 20.8% between 2023 and 2033. The lateral flow segment is estimated to be the largest segment of the rapid testing market, accounting for 36% of the market in 2023 (Source: Precedence Research: 2024 Rapid Diagnostics Market report). This growth is being driven in part by reduced barriers to adoption for lateral flow technology ("LFT") due to the widespread adoption of LFT during the COVID-19 pandemic. According to Statista (
Tests for COVID-19 most impacted countries worldwide 2022 | Statista
), there were 1.15 billion and 0.5 billion COVID-19 lateral flow tests performed in the US and the UK respectively by December 2022. Most people in the USA, the UK and other western countries have performed a lateral flow test and understand the technology. The second growth driver is innovation. We believe the COVID-19 pandemic has driven a second wave of innovation in the lateral flow market and this is driving greater use of the technology as the usability and performance of lateral flow technology improves.
Further growth drivers include the expansion in infectious disease testing, growing use within chronic disease management, rising consumer interest and growth in home testing kits, integration of digital technologies, and regulatory and reimbursement developments.
We remain confident that Abingdon Health's knowledge leadership position in the lateral flow industry and our integrated service offering will continue to lead to sustainable revenue growth. Our key objective remains to move the company to sustained positive cashflow and we are making solid progress towards this objective.
Our strategy
Our mission at Abingdon Health is to improve life by making rapid results accessible to all. We achieve this by supporting our customers, as an integrated lateral flow CRO & CDMO, in developing and manufacturing lateral flow tests across a range of sectors including clinical (human health), animal health, plant pathogen and environmental testing.
Our technology focus continues to be on the lateral flow market which is large and growing. Our acquisitions of IVDeology and Compliance Solutions (Life Sciences) give us access to other regulatory, clinical testing, and quality assurance elements of the lateral flow market and also provide access to adjacent markets. Key drivers of the growth in the lateral flow sector include reduced barriers to adoption of lateral flow technology following widespread lateral flow testing during the COVID-19 pandemic, innovation in the lateral flow market, as well as other factors such as a drive towards the decentralisation of testing to improve patient and economic outcomes, the increase in rates of infectious disease and the emergence of new pathogens; and the increased demand from consumers for diagnostic tools to enable them to manage their own health.
Abingdon Health's focus within the lateral flow market is two-fold:
1) Lateral flow CRO/CDMO - providing 89% of 2023/4 revenues
Our core service proposition is to provide our customers with a fully integrated, contract research and contract development and manufacturing service enabling Abingdon to manage the lateral flow development projects in full, from '
idea through to commercial success
', and to provide large-scale automated manufacturing. The CRO and CDMO business model, well-established in the pharmaceutical industry, has direct application to the medical diagnostics market, and our contract services include R&D, optimisation and scale-up, technical transfer and manufacturing as well as added-value services such as reagent development, regulatory and clinical trial support and packaging design and kitting service provision. The ability to offer this range of services, providing outsourcing options to our customer base, continues to resonate well. It has been pleasing to see a number of customers benefit from this integrated service in the year utilising Abingdon not only for development, scale-up and technical transfer but also, for example, regulatory and analytical laboratory support. We continue to drive greater awareness of the capabilities of, and innovation in, lateral flow technology through a regular cadence of blogs and articles and we also attend third party workshops and conferences to promote the use of lateral flow technology and share knowledge. To that end we were delighted to sponsor the 2024 Next Generation Diagnostics Conference in Washington DC in August 2024.
2) Lateral flow product sales & distribution - providing 11% of 2023/4 revenues
We continue to build a route to market initially within Europe for lateral flow self-tests. Our route to market will be a combination of both direct sales, on Amazon or through our website
www.abingdonsimplytest.com
and through retail and distribution agreements. We have established our own self-test lateral flow brand, Abingdon Simply Test‚Ñ¢, which currently includes 16 self-test products.
Going forward, the core element of our strategy is to be a preferred supplier of lateral flow tests to major retailers, in essence a trusted partner in the sourcing of tests both through our own CDMO customer base and externally through third parties. We were therefore delighted to announce the launch of self-tests for Vitamin D and Ferritin (Iron) in March 2024 and saliva pregnancy test (May 2024) with Boots under the Boots own-label brand. We continue to pursue opportunities to expand the number of products we supply to Boots and other major European retailers with a focus on the provision of own-label solutions.
We regard our lateral flow sales & distribution platform as complementary to our CRO/CDMO business. It is intended to provide support to a number of our CDMO customers who are developing self-tests, with a ready-made route to market to drive early commercial adoption. The first such example was the launch of SalistickTM, the first ever saliva pregnancy test, in the UK. The product is currently distributed in a number of major retailers including Superdrug and Boots.
Performance in the year
We were pleased with the financial performance in FY24 with revenue growth of 52% compared to FY23. The Group's revenues were¬†¬£6.1m (2023: ¬£4.0m) and excluding the impact of the acquisition of IVDeology in May 2024, FY24 revenues were ¬£6.0m which was 49% higher than FY23.
Our CRO/CDMO business grew 51% year-on-year. This strong revenue growth arose from an increase in the number of customers utilising our contract development, scale-up, technical transfer and manufacturing services; and an expansion in our range of services such as regulatory support. Our model is based on bringing customers through the development process and into manufacturing and then supporting these customers in the long-term as manufacturing and regulatory customers. We saw three customer products transition into manufacturing in FY24: Salignostics (saliva pregnancy test), LoopDX (sepsis) and Up Front Diagnostics (stroke). We expect further technical transfers to transition into manufacturing in FY25 to continue to build upon our manufacturing customer base.
We were also pleased to see our Product business revenues grow strongly during FY24 with 56% year-on-year growth. We benefited in H2 FY24 from the launch of three lateral flow tests with Boots and in FY25 we will build on this progress with continued expansion of our product range and sales and distribution platform to generate further Product sales growth.
Acquisition of IVDeology
In May 2024 Abingdon acquired
IVDeology, a UK-based leading provider of regulatory consultancy support to an international customer base in the in vitro diagnostics sector for total consideration of up to ¬£700,000.
IVDeology provides a range of regulatory services including those in support of IVDR (the In Vitro Medical Devices Regulation (EU) 2017/746) for the EU market, UKCA (UK Conformity Assessed) marking for the UK market, and FDA support for the US market to an international customer base. The acquisition strengthened Abingdon's existing regulatory service, knowledge leadership and expertise in the regulatory area. The regulatory environment for in vitro diagnostics, including lateral flow tests, is going through a period of significant change with the implementation of IVDR in Europe and the creation of UKCA marking in the UK. In addition, there have been recent changes to the classification of various categories of lateral flow products in the USA. These changes create opportunities for Abingdon to support existing and new customers in navigating this landscape.
The acquisition was satisfied by the issue of 5 million ordinary shares of 0.0025 pence each in Abingdon Health plc ("Ordinary Shares") to the owners of IVDeology at an issue price of 10 pence per Ordinary Share, equating to ¬£0.5m. In addition, subject to achieving certain revenue targets in the two financial years following acquisition, an earn-out of ¬£0.2m will be payable at the time. In its financial year ending 31 January 2024, the IVDeology group generated combined turnover of ¬£392k; resulting in a combined loss before tax of ¬£30k.
Concert Party
On 30 August 2023, we announced the break-up of a concert party established at IPO which effectively prevented those shareholders who together were holding approximately 35% of the issued share capital in Abingdon being able to buy additional shares. Now that this 'IPO concert party' has been split into three smaller concert parties, those shareholders in the original concert party may now buy additional shares.
Team
During the financial year our average staff numbers were 85 (2023: 82). As at 31 August 2024 there were 120 employees within Abingdon Health following the completion of the acquisition of Compliance Solutions (Life Sciences) which had 36 employees as at 31 August 2024.
We would like to thank all of the Abingdon Health team for their efforts in the last year, which resulted in significant revenue growth for the Business. We would also like to welcome the IVDeology and Compliance Solutions (Life Sciences) teams to the Group.
Governance and People
Mary Tavener is the Company's Senior Independent Non-Executive Director, having been appointed in November 2020 prior to listing on AIM. Abingdon Health's other Non-Executive Director is Dr Chris Hand who is a co-founder of Abingdon Health, Non-Executive Chairman, and retains a significant shareholding in the Company as noted in the Directors Report.
Melanie Ross, Chief Financial Officer, left the business in October 2023 and we would like to thank Melanie for her service.
Our Audit Committee and Remuneration Committee currently comprises Mary Tavener (Chair) with Chris Hand. The Executive Director Chris Yates is invited to attend as required from time-to-time.
The Board has concluded that at this time the Group does not currently require a Nominations Committee but will review this assessment on a regular basis including discussing the matter with its Nominated Advisor.
The Board remains focused on ensuring its own effectiveness and that of the governance processes throughout the Group, and that these governance structures remain fit for purpose as the Group develops and grows over time. Mary Tavener is Abingdon Health's only Independent Non-Executive Director and, as such, the Board's current composition does not comply with the requirements for a minimum of two Independent Non-Executive Directors under the QCA Corporate Governance Code, being the corporate governance code that the Company has chosen to apply. Although this is not in compliance with the Code, given the size of the Group, the Board believed that this met the needs of the business at that time. As the business continues to grow and expand, there is now a need to improve the strength and depth of the Board and a process has begun to recruit a new Chief Financial Officer and an additional new non-executive director. Both recruitment processes are underway, and the Board will update shareholders in due course.
USA and Board Management
To accelerate the Group's commercial progress, and to gain additional access to the US market, Abingdon is planning to open a commercial office and R&D laboratory in the United States during Q4 of calendar year 2024. Chris Yates, CEO, has been asked to focus on global commercial growth, establishment of an Abingdon Health USA-based subsidiary and management of US operations. To facilitate this expansion, Chris Hand will be appointed Executive Chairman. These changes will be effective from 15 October 2024. Chris Hand will manage day to day R&D, operational and financial activities with Chris Yates focused on organic revenue growth, cross-selling between Group members' (Abingdon Health, Compliance Solutions (Life Sciences), IVDeology) customers, and potentially by acquisition. Chris Yates will focus his time on growing Abingdon's international presence specifically in the United States. As an illustration of the importance of the US market the United States economy is c.49% larger than that of the European Union (Source: World Bank); and it is also the largest diagnostics market globally, accounting for 39% of the global market (Source: Vision Research Reports).
Post Balance Sheet Events
Acquisition of Compliance Solutions (Life Sciences)
In August 2024 Abingdon completed the acquisition of Compliance Solutions (Life Sciences) group
which specialises in meeting regulatory requirements of its international and UK client base in the¬†in vitro diagnostic (IVD) and medical device markets.¬†The Compliance Solutions group's¬†team (currently c.36 employees) provides consultancy services, ranging from preparation of technical files for regulatory approvals, clinical strategy advice and protocol design and regulatory inspection gap analysis; design, implementation and maintenance of quality management systems; technical file and design file reviews, clinical evaluation reports and biological safety evaluations; and internal audit programmes; supplier audits, pre-audit preparations (e.g. FDA, MHRA, Notified Body, unannounced) and mock Notified Body/FDA audits. In its financial year ending 30 June 2023, the main trading entity Compliance Solutions (Life Sciences) Limited generated turnover of ¬£2,716k; resulting in EBITDA of ¬£393k.
The Compliance Solutions Group's¬†activities are complementary to those of the Abingdon Group and the recently acquired IVDeology; and increase the breadth and depth of the Group's regulatory expertise.
Furthermore, there is, in the Board's opinion, the opportunity to cross-sell the Group's services, such as lateral flow development and manufacture and analytical laboratory support, into the¬†Compliance Solutions Group's¬†customer base and vice versa.
The maximum consideration of¬†¬£3.2m¬†comprises:
i)
cash of¬†¬£1.36m paid as follows:¬†¬£700,000¬†on completion and then 3 equal payments of¬†¬£220k¬†at the end of the first, second and third month following completion; and
ii)
the sum of¬†¬£1.0m satisfied by the issue of 9,216,590 Ordinary Shares; and
iii)
an amount in cash equal to the amounts received by Compliance Solutions (Life Sciences) Limited in respect of certain aged debtors in the 24-month period from Completion, subject to a maximum amount of¬†¬£340k; and
iv)
subject to achieving certain revenue targets in the period starting on the first anniversary of the acquisition and ending on the second anniversary of the Acquisition, an earn out of up to¬†¬£0.5m¬†to be satisfied by the issue of such number of further Ordinary Shares.
Fundraising
In August 2024 we completed a fundraising which raised gross proceeds of ¬£5.6m (net proceeds of ¬£5.1m). The fundraising comprised a Placing with institutional investors which raised gross proceeds of ¬£5.2m and a retail offer which raised gross proceeds of ¬£0.4m. The use of proceeds is summarised as follows:
Product development
¬£3.0m
Analytical laboratory service expansion
¬£1.0m
Working capital and placing costs
¬£1.6m
Product development
The Board proposes to use up to¬†¬£3.0m¬†of the proceeds to enhance the Group's product offering through development of lateral flow self-tests alongside use of the Group's patented AppDx¬Æ technology - a smartphone based lateral flow test reader.
Expansion of analytical laboratory service
The Board also proposes to use up to¬†¬£1.0m of the proceeds of the Placing to strengthen its analytical laboratory service. The Group has been providing this service since 2023 as part of its strategy of providing a comprehensive contract development and manufacturing service and supporting its customers in bringing products to market.
The Placing will allow the Group to expand its in-house analytical laboratory services and also extend these capabilities to a range of other test formats including PCR, LAMP, other isothermal amplification assays, antigen and antibody detection immunoassays and other point-of-care assays, in addition to supporting basic research. The laboratory will be based at the Group's Doncaster site.
Outlook
& Funding
Cash at the end of the financial year was ¬£1.4m and as at 4 October 2024, following the completion of the fundraising and the acquisition of Compliance Solutions was ¬£4.5m. We believe we have sufficient cash resources to fund progress beyond 12 months from the signing date of the accounts, with our priority continuing to be moving the Company to a positive cashflow position, having achieved a cashflow positive quarter in Q4-FY2024.
Our strategic focus is on growing our CRO/CDMO business and expanding the reach of our lateral flow product range.
The recent acquisitions of IVDeology and Compliance Solutions (Life Sciences), and the further investment in expanding our analytical laboratory service, mean that we can offer a comprehensive service to our customers to fully support them in bringing their innovative products to market. We will also continue to grow our European distribution platform for self-tests both through increasing the number of retailer and distribution agreements in place and secondly through broadening the self-test product range including those developed in partnership with our CRO/CDMO customers.
Our key financial priorities are to grow our revenues and reduce our cash-burn through continued close cost management. To this end we will continue to focus our team's activities on CRO/CDMO and associated regulatory, QA and analytical laboratory business to provide near-term revenues.
As a CRO/CDMO focused on lateral flow technology with a well-established track record of bringing products from "idea to market" we believe we are well-placed to support a broad range of customers across the clinical (point of care & self-test), pharmaceutical, animal health, food, plant pathogen and environmental testing markets. We believe our full-service contract service proposition strongly resonates with customers, and we look forward to continuing to support our customers in bringing their innovative tests to market.
We would like to thank all our employees for their hard work, dedication and commitment during the past year as we continued to grow our revenues. We are confident that our contract services customer base and our current growing pipeline means we are well positioned to grow our business and deliver shareholder value going forward.
We would like to thank shareholders for their support.
Operating and Financial Review
Revenue and Margins
The Business delivered strong revenue growth in the period, growing 52% when compared to the previous financial year, and 49% when excluding the impact of the IVDeology acquisition which completed in May 2024.
Revenue by Geographical Market
Geographical Market
2024 ¬£m
% *
2023 ¬£m
%*
Growth/
(Decrease)
UK
2.6
41%
1.3
32%
94%
USA/Canada
2.0
33%
0.8
21%
137%
Europe
1.2
20%
1.7
41%
(26)%
ROW
0.3
6%
0.2
6%
47%
Total
6.1
100%
4.0
100%
52%
*percentages are calculated on exact totals and not the rounded amounts shown above
Revenue by Operating Segment
Operating Segment
2024 ¬£m
%*
2023 ¬£m
%*
Growth
Contract Development
3.2
54%
2.2
57%
45%
Contract Manufacturing
1.3
20%
1.1
26%
19%
Regulatory
0.9
15%
0.3
7%
236%
Products
0.7
11%
0.4
10%
56%
Total
6.1
100%
4.0
100%
52%
*percentages are calculated on exact totals and not the rounded amounts shown above
Contract Development (R&D activity based on a fee for service and manufacturing of validation batches) increased 45% year on year because of both increased contract development activity and more projects moving into technical transfer.
Contract Manufacturing (manufacture of products for third parties) increased 19% over the period.
Regulatory services revenues increased by 236% and excluding the impact of the acquisition of IVDeology revenues increased by 200% compared to the prior year. The increase was the result of expanding the services offered to our customers and providing a more integrated service solution to customers looking to take projects from idea to commercial success.
Product sales (own products) increased by 56% in the relevant period benefiting from the launch of three products with Boots in the second half of the financial year.
Gross margin in the financial year was 60% (2023: 51%) with the improvement driven by operational gearing benefits from increased revenues.
Administrative expenses reduced to ¬£5.0m (2023: ¬£5.2m) following continued cost management during the year despite the ongoing challenges operating in an inflationary environment.
Adjusted EBITDA
The Business uses adjusted EBITDA as a measure, as this excludes items which can distort comparability as well as being the measure of profit that most accurately reflects the cash generating activities of the Group. The reconciliation of these adjustments is as follows:
Year Ended 30 June 2024
¬£'000
Year Ended 30 June 2023
¬£'000
Adjusted EBITDA
(1,132)
(2,893)
Share based payment expense
(48)
(28)
Impairment charges
-
(86)
Gain on Lease Modification
-
390
Non-recurring legal and professional fees
(32)
(33)
Non-recurring redundancy costs
-
(162)
Non-recurring settlement payment
(108)
-
Gain on settlement
373
-
Other exceptional costs
-
(88)
Statutory EBITDA
(947)
(2,900)
Amortisation
(27)
(29)
Depreciation
(399)
(659)
EBIT
(1,373)
(3,588)
Adjusted EBITDA loss in the period was ¬£1.1m (2023: loss ¬£2.9m), a significant decrease on the prior year driven by both increases in the revenue and cost reductions year on year.
Headcount in the Group was an average of 85 (2023: 82). Staff costs overall, within both cost of sales and administrative costs, were ¬£4.3m (2023: ¬£4.0m), including ¬£0.1m of non-recurring costs (2023: ¬£0.2m) set about in the table above. Headcount at the end of the year was 84 and included the addition of 8 employees following the acquisition of IVDeology in May 2024.
Premises costs were ¬£0.7m in the year (2023: ¬£0.6m). Prior year underlying premises costs were ¬£0.9m when adjusted for the one off ¬£0.3m gain (in exceptionals) due to a release of the Right of Use asset resulting from releasing its contractual lease obligations on space at its York site. In addition, a dilapidations provision of ¬£100k was included as a prior year adjustment to take account of the legal requirement under the Doncaster lease to return the condition of the property back to that in which the property was prior to the commencement of the lease. Given our investment in opening an analytical laboratory in Doncaster and the likelihood of extending the lease beyond 2 November 2026 it is the Board's view that the likelihood of this provision crystallising in the short-to-medium-term is remote. Note 11 below provides further details.
Professional costs (excluding exceptionals) in the year were ¬£0.3m (2023: ¬£0.4m).
Marketing and Travel costs were ¬£0.2m (2023: ¬£0.2m) as the Business continued to attend exhibitions and visit customers in person.
Cash Resources
Net cash outflow from operating activities was ¬£1.7m (2023: inflow ¬£0.9m) with the previous financial year positively impacted by the settlement of outstanding liabilities from the Department of Health and Social Care.
Overall, we saw a net cash outflow of ¬£1.8m and a closing cash position of ¬£1.4m (2023: ¬£3.2m).
Financing
Post-year end, in August 2024 the business completed a fundraise which raised gross proceeds of ¬£5.6m (net proceeds of ¬£5.1m).
Key Performance Indicators ("KPIs")
The business considers various factors when determining the KPI measures and these evolve as the business changes to meet differing market demands to ensure continued success. In this financial year the KPI measures focused on revenue growth, reduction in (adjusted) EBITDA loss and reduction in the cash burn of the business. These metrics are felt to be the most important to ensure that the business achieves cash breakeven and profitability. Other internal measures introduced in the new financial year will focus on contract progression from Development to Manufacturing, as well as the number of tests manufactured per FTE.
Earnings per Share
Basic and diluted earnings per share was a loss of 0.42p in the period and basic and diluted adjusted EPS was a loss of 0.37p in the same period.
EPS
Basic EPS Loss
0.42p
Loss before taxation attributable to equity owners of the parent
¬£(1,399)k
Add: Share Based Payments
¬£48k
Add: Non recurring legal fees
¬£32k
Add: Non recurring settlement payment
¬£108k
Add: Depreciation and Amortisation
¬£426k
Add: Finance Costs
¬£26k
Deduct: Gain on settlement
¬£(373)k
Adjusted Loss attributable to Shareholders
¬£(1,132)k
Adjusted Basic EPS Loss
0.37p
The basic EPS calculated above uses a weighted average number of ordinary shares of 304,732,264.
The weighted average number of ordinary shares above includes 182,316,812 deferred shares of 0.025p each. Technically this is correct. However, it should be noted that the deferred shares are non-voting shares, with no rights to dividends, but holders of deferred shares are entitled to receive the nominal value of that share (0.0025 pence sterling) once on a return of capital, a repurchase of those shares by the Company or in connection with a sale of those shares. The total nominal value of all the deferred shares is ¬£46k.
Consolidated Statement of Comprehensive Income
For the Year Ended 30 June 2024
Year ended 30 June 2024
Year ended 30 June 2023
as restated
¬£'000
¬£'000
Revenue
6,135
4,045
Cost of sales
(2,456)
(1,970)
Gross profit
3,679
2,075
Administrative expenses
(5,070)
(5,220)
Other income
259
252
Adjusted EBITDA (before adjusting items)
(1,132)
(2,893)
Amortisation
(27)
(29)
Depreciation
(399)
(659)
Impairment charges
-
(86)
Share based payment expense
(48)
(28)
Non-recurring legal, professional and fundraising fees
(32)
(33)
Non-recurring redundancy costs and termination awards
(108)
(162)
Lease modification
-
390
Other exceptional costs
-
(88)
Gain on settlement
373
-
Operating loss
(1,373)
(3,588)
Finance income
31
89
Finance costs
(57)
(75)
Loss before taxation
(1,399)
(3,574)
Taxation credit
128
105
Loss for the financial period
(1,271)
(3,469)
Other comprehensive income for the year net of tax
-
-
Total comprehensive loss for the year
(1, 271)
(3,469)
Attributable to:
Equity holders of the parent
(1, 271)
(3,469)
Basic losses per share (pence)
(0.42)
(1.14)
Diluted losses per share (pence)
(0.42)
(1.14)
Consolidated Statement of Financial Position
As at 30 June 2024
30 June2024
30 June
2023
30 June
2022
as restated
as restated
¬£'000
¬£'000
¬£'000
Non-current assets
Goodwill
379
-
-
Other intangible assets
153
90
36
Property, plant, and equipment
997
1,257
1,840
Investment
13
-
-
1,542
1,347
1,876
Current assets
Inventories
441
329
534
Trade and other receivables
1,466
1,147
7,844
Income tax receivable
201
50
183
Cash and cash equivalents
1,440
3,236
2,397
3,548
4,762
10,958
Total assets
5,090
6,109
12,834
Current liabilities
Trade and other payables
1,704
2,033
5,059
Borrowings
-
-
115
Obligations under leases
120
87
150
1,824
2,120
5,324
Non-current liabilities
Borrowings
722
708
435
Obligations under leases
207
224
580
Provisions
88
85
82
1,017
1,017
1,097
Deferred tax liabilities
-
-
-
Total liabilities
2,841
3,137
6,421
Net assets
2,249
2,972
6,413
Equity
Attributable to the owners of the parent:
Share capital
77
76
76
Share premium
30,808
30,309
30,309
Share based payment reserve
124
80
153
Accumulated deficit
(28,760)
(27,493)
(24,125)
Total equity
2,249
2,972
6,413
Consolidated Statement of Changes in Equity
For the Year Ended 30 June 2024
Share Capital
Share premium
Share based payment reserve
Accumulated deficit
Total equity attributable to owners of the parent
¬£'000
¬£'000
¬£'000
¬£'000
¬£'000
Balance at 1 July 2022 (as restated)
76
30,309
153
(24,125)
6,413
Year ended 30 June 2023:
Profit and loss
-
-
-
(3,469)
(3,469)
Total comprehensive loss for the year
-
-
-
(3,469)
(3,469)
Other movements:
Share option expense
-
-
28
-
28
Share options exercised
-
-
(4)
4
-
Share options cancelled
-
-
(97)
97
-
Balance at 30 June 2023 (as restated)
76
30,309
80
(27,493)
2,972
Year ended 30 June 2024:
Profit and loss
-
-
-
(1,271)
(1,271)
Total comprehensive loss for the year
-
-
-
(1,271)
(1,271)
Other movements:
Issue of shares
1
499
-
-
500
Share option expense
-
-
32
-
32
Earn-out consideration classified as share-based payment
-
-
16
-
16
Share options cancelled
-
-
(4)
4
-
Balance at 30 June 2024
77
30,808
124
(28,760)
2,249
Consolidated Statement of Cash Flows
For the Year Ended 30 June 2024
30 June2024
30 June2023
As restated
¬£'000
¬£'000
Cash flows from operating activities:
Loss for the year
(1,271)
(3,469)
Adjustments for:
Other income
(255)
(252)
Net finance cost/(income)
26
(14)
Tax credit
(128)
(105)
Amortisation and impairment of intangible assets
27
29
Share-based payment expenses
48
28
Depreciation and impairment of property, plant and equipment
399
745
Loss on sale of property, plant and equipment and intangible assets
33
-
Changes in working capital:
(Increase)/decrease in inventories
(112)
205
(Increase)/decrease in trade and other receivables
(297)
6,647
Decrease in trade and other payables
(335)
(3,180)
Cash generated (used in)/from operations
(1,865)
634
Interest paid (including leases)
(25)
(48)
Income taxes received
231
325
Insurance claim proceeds
-
2
Net cash (outflow) / inflow from operating activities
(1,659)
913
Interest received
31
89
Purchase of intangible assets
(6)
(82)
Purchase of property, plant and equipment
(35)
(75)
Proceeds on disposal of property, plant and equipment
-
1
Acquisition of other investments
(13)
-
Net cash used in investing activities
(23)
(67)
Consolidated Statement of Cash Flows
For the Year Ended 30 June 2024
30 June2024
30 June2023
¬£'000
¬£'000
Financing activities
Cash withheld for SAYE scheme
-
(1)
Proceeds from new bank loans and borrowings
-
250
Payment of loans
-
(115)
Payment of lease obligations
(114)
(141)
Net cash used in from financing
(114)
(7)
Net (decrease)/increase in cash and cash equivalents
(1,796)
839
Cash and cash equivalents at beginning of the year
3,236
2,397
Cash and cash equivalents at end of the year
1,440
3,236
Recognised in the Statement of Financial Position as:
Cash at bank and in hand
1,369
3,236
Restricted cash
71
-
1,440
3,236
The Group holds the sum of ¬£70,628 in trust in a separate interest-bearing account on behalf of an original shareholder in Molecular Vision from whom Abingdon Health acquired its shares in Molecular Vision in 2014.
Abingdon has been unable to transfer this consideration to the original shareholder and has been advised by its legal advisers that the consideration needs to be held in a separate account for a period of 12 years (until November 2026) and at this time, if the transfer to the shareholder has not been made, the consideration will be paid into court.
Notes to the Financial Statements
For the Year Ended 30 June 2024
Company information
Abingdon Health PLC ("the Company") is a public limited company domiciled and incorporated in England and Wales. The Company is quoted on the London Stock Exchange's Alternative Investment Market ("AIM"). The registered office is York Biotech Campus, Sand Hutton, York, YO41 1LZ. The consolidated financial information (or "financial statements") incorporates the financial information of the Company and entities (its subsidiaries) controlled by the Company (collectively comprising the "Group").
The principal activity of the Group is to develop, manufacture and distribute diagnostic devices and provide consultancy services to businesses in the diagnostics sector.
Basis of preparation
The financial information set out in this preliminary announcement does not constitute statutory accounts as defined by section 434 of the Companies Act 2006.
The financial information for the year ended 30 June 2024 and the year ended 30 June 2023 does not constitute the Company's statutory accounts for those years. Statutory accounts for the year ended 30 June 2023 have been delivered to the Registrar of Companies. The statutory accounts for the year ended 30 June 2024 were approved by the Board on 7 October 2024 and will be delivered to the Registrar of Companies in due course. The statutory accounts for the period ended 30 June 2024 will be posted to shareholders at least 21 days before the Annual General Meeting and made available on the Group's
website
.
The Group's statutory financial statements for the year ended 30 June 2024, from which the financial information presented in this announcement has been extracted, were prepared in accordance with UK adopted international accounting standards ("IFRS"). The financial statements have been prepared on the historical cost basis with the exception of certain items which are measured at fair value as disclosed in the principal accounting policies set out in the Group's Annual Report. These policies have been consistently applied to all years presented.
The preparation of financial statements in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results ultimately may differ from these estimates.
The auditor's reports on the accounts for 30 June 2024 and 30 June 2023 were unqualified and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.
Critical judgements
The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements:
Right of use asset recognition
Management have assessed each lease liability for recognition under IFRS 16 and recognised a right of use asset where appropriate. Further explanation of this judgement will be provided in the statutory accounts.
One lease includes a material component of service charge by comparison to the headline rental payments, where this service charge partially covers shared areas and facilities which would normally form part of a rental price. The Directors have applied judgement in splitting out a rent-like component from the service charge of ¬£12,000 which qualifies for capitalisation as a right of use asset. In the current year the lease was reassessed due to an inflationary rental increase, the accounting estimate has been applied consistently.
Revenue recognition
In line with IFRS 15 management are required to determine appropriate revenue recognition points for all revenue streams. Where multiple contracts are entered into with a single counterparty any instalment payments are not considered to be a key indicator of the satisfaction of a performance obligation, although linked contracts with a counterparty are considered in conjunction when identifying the appropriate point for revenue recognition.
Deferred consideration
A portion of the consideration for the acquisitions in the year was a contingent deferred consideration. Under IFRS 3 the 'earn-out' contingent deferred consideration has been treated as employee remuneration. The earn-out is payable in 2 years and is dependent on cumulative revenue. Management are very confident that this will be payable, particularly with reference to expected revenue synergies. Accordingly, a discount rate akin to a borrowing rate has been applied.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:
Valuation and impairment of cash generating units (including goodwill)
Goodwill is tested annually for impairment as part of a cash generating unit ("CGU"). The test considers future cash flow projections of each CGU on a group basis, as the group as a whole is considered to be a single CGU. In the current year, two tests have been performed, a discounted cash flow model and a value-in-use model, which have both approximated to the same value.
Where the discounted cash flows are less than the carrying value of the CGU, an impairment charge is recognised for the difference, which for the prior year will be shown in Disclosure Note 5 of the statutory accounts. Further analysis of the estimates, judgements and sensitivities in the estimates are disclosed in Disclosure Note 13 of the statutory accounts.
Useful lives and impairment of intangible assets
The Group have estimated the expected useful lives of intangible assets arising from acquisitions based on qualitative and quantitative data. For identifiable intangible assets arising on acquisition of a business, the useful lives are determined based on the lower end of benchmark data. Details of these amortisation rates are set out in the accounting policies. Useful lives are regularly reviewed and should management's assessment of useful lives change then amortisation charges in the financial statements would be adjusted and carrying amounts of intangible assets would change accordingly.
Going concern
Since the end of the last financial year, the Group completed a fundraising which raised ¬£5.6m (¬£5.1m net of expenses) from institutional and retail investors. The Group remains focused on growing its CRO/CDMO revenues and continuing to maintain control over this operational cost base in order to reduce the Group's cashburn.
The Directors have prepared cash flow forecasts under a number of scenarios The budget is the base case scenario and this is sensitised to consider plausible downside scenarios for example significantly reducing revenue growth in the next fiscal year.
These forecasts cover a period of at least 12 months from the expected date of approval of the financial statements and the Business continues to evaluate financial forecasts on a regular basis. The focus of the group remains on expanding its fee for service CRO/CDMO model and any increase in headcount and/or operational footprint will be on the basis of an increase in the number of secured contracts, revenue and cash inflows. At 30 June 2023 the bank balance was ¬£1.4m. Cash as at 4 October was ¬£4.5m. The Board is satisfied that based on the above and the current forecasts, there is sufficient headroom and concluded that it is appropriate to prepare the Annual Report and Accounts on a going concern basis.
The Directors have prepared the cashflow forecasts.
Non-recurring income and costs
The Group seeks to highlight certain items as exceptional operating income or costs. These are considered to be exceptional in size, frequency and/or nature rather than indicative of the underlying day to day trading of the Group. These may include items such as acquisition costs, restructuring costs, obsolescence costs, employee exit and transition costs, legal costs, profits or losses on the disposal of subsidiaries, and loan impairments. All of these items are charged or credited before calculating operating profit or loss.
The Directors apply judgement in assessing the particular items, which by virtue of their size and nature are disclosed separately in the Statement of Comprehensive Income and the notes to the financial statements as non-recurring income and costs. The Directors believe that the separate disclosure of these items is relevant to understanding the Group's financial performance.
Dilapidations
The Group have estimated a dilapidation provision that will fall due at the end of their operating lease term. The provision is an estimate and has been calculated by predicting both a wear and tear and capital element. The provision is discounted to its net present value as at the financial year end (Disclosure Note 21 in the statutory accounts).
1. Revenue
The Group applies IFRS 15 'Revenue from contracts with customers'. Under IFRS 15, the Group applies the 5-step method to identify contracts with its customers, determine performance obligations arising under those contracts, set an expected transaction price, allocate that price to the performance obligations, and then recognises revenues as and when those obligations are satisfied.
Segmental analysis of revenue
2024
2023
¬£'000
¬£'000
Product sales
650
418
Contract manufacturing
1,258
1,058
Contract development
3,327
2,301
Regulatory
900
268
Total revenue from contracts with customers
6,135
4,045
Revenue analysed by geographical market
2024
2023
¬£'000
¬£'000
United Kingdom
2,538
1,307
Europe (excluding Belgium)
737
1,179
Belgium
498
479
USA & Canada
2,039
861
Rest of the World
323
219
6,135
4,045
All revenue received in the current and comparative years has been recognised at a point in time in accordance with the Group's revenue recognition policy.
2. Taxation
2024
2023
¬£'000
¬£'000
Current tax
UK Corporation tax on loss for the current year
(77)
46
Adjustments in respect of prior years
(25)
(151)
Total current tax
(102)
(105)
Deferred tax
Origination and reversal of temporary differences
(26)
-
Impact of change in tax rates
-
-
Total deferred tax
(26)
-
Total tax credit
(128)
(105)
The charge for the year can be reconciled to the profit per the Consolidated Statement of Comprehensive Income as follows:
2024
2023
As
A
¬£'000
¬£'000
as restated
Loss before taxation
(1,399)
(3,574)
Expected tax credit based on a corporation tax rate of 25%(2023 - 20.5%)
(350)
(733)
Tax effect of expenses that are not deductible in determining taxable loss
30
(55)
Income not taxable
(95)
-
Change in unrecognised deferred tax asset
329
851
Timing differences between depreciation and capital allowances
93
(5)
Unrecognised deferred tax on share-based payments
8
6
Prior year adjustment
-
(158)
Research and development
(126)
(20)
Unrecognised deferred tax on movement on provisions
(3)
(5)
Deferred tax on intangibles recognised on acquisition
(26)
-
Other differences
12
14
Total tax credit
(128)
(105)
The UK corporation tax rate was 19% until 1 April 2023 when it increased to 25%, giving a hybrid tax rate of 20.5% for the prior year.
Deferred tax balances at the reporting date are measured at 25%, which is the effective rate in place (2023: 25%; 2022: 19%).
4. Dividends
No dividends were paid in the current or prior year.
5. Earnings per share
The calculation of the basic and diluted earnings per share is based on the following data:
2024
2023
as restated
Earnings used in calculation (¬£'000)
(1,271)
(3,469)
Weighted average number of ordinary shares
304,737,264
304,033,363
Basic EPS (pence/share)
(0.42)
(1.14)
Weighted average number of dilutable shares
308,202,227
305,820,420
Diluted EPS (pence/share)
(0.42)
(1.14)
In each period there were share options outstanding. As at 30 June 2024, options which are out of the money are excluded from the calculation of the weighted average number of dilutable shares.
The Directors use adjusted earnings before certain non-recurring costs ("Adjusted Earnings") as a measure of ongoing performance and profitability. These non-recurring costs are presented as separate items on the face of the Consolidated Income Statement.
The calculated Adjusted Earnings for the current and comparative periods are as follows:
2024
2023
¬£'000
¬£'000
as restated
Loss before taxation attributable to equity owners of the Parent
(1,399)
(3,574)
Share-based payment costs
48
28
Impairment charges
-
86
Non-recurring legal fees
32
33
Non-recurring employee redundancy costs
-
162
Non-recurring settlement payment
108
-
Depreciation and amortisation
426
688
Net finance cost/ (income)
26
(14)
Lease modification
-
(390)
Other exceptional costs
-
88
Gain on settlement
(373)
-
Adjusted Earnings
(1,132)
(2,893)
Basic and diluted Adjusted Earnings per share (pence/share)
(0.37)
(0.94)
The calculation of Adjusted Earnings is consistent with the presentation of Adjusted Earnings before Interest, Tax, Depreciation, and Amortisation, as presented on the face of the Statement of Comprehensive Income. This adjusted element also removes non-recurring items, as explained further in Disclosure Note 5 of the statutory accounts. The Directors have presented this Alternative Performance Measure ("APM") because they feel it most suitably represents the underlying performance and cash generation of the business, and allows comparability between the current and comparative period in light of the rapid changes in the business (most notably its admission to AIM and associated costs), and will allow an ongoing trend analysis of this performance based on current plans for the business. Tax is excluded from this APM because the Group has significant tax losses and so the tax charge is not representative of the cash generated.
6. Share capital and reserves
2024
2023
Ordinary share capital
Authorised
Number
Number
Ordinary shares of 0.025p each
126,716,822
121,716,822
Deferred shares of 0.025p each
182,316,812
182,316,812
309,033,634
304,033,634
Allotted and fully paid
Number
Number
Ordinary shares of 0.025p each
126,716,822
121,716,822
Deferred shares of 0.025p each
182,316,812
182,316,812
309,033,634
304,033,634
¬£'000
¬£'000
Ordinary shares of 0.025p each
32
31
Deferred shares of 0.025p each
45
45
77
76
Reconciliation of movements during the year:
Number
At 1 July 2023
304,033,634
Issue of new shares
5,000,000
At 30 June 2024
309,033,634
During the year, on 10 May 2024, there was a share issue of 5,000,000 shares with a nominal value of ¬£0.00025 as a part of the IVDeology acquisition. The total amount paid per share amounted to ¬£0.1 resulting in ¬£1,250 recognised in Share Capital and ¬£498,750 in Share Premium.
Reserves of the Company represent the following:
Share capital
- Shares in the Company held by shareholders at a proportional level with equal voting rights per share.
Share premium
- Excess over share capital of any investments.
Retained earnings
- This comprises the accumulated trading results of the Group.
Share-based payment reserve
- This reserve comprises the fair value of options share rights recognised as an expense. Upon exercise of options or performance share rights, any proceeds.
7. Share options
Group & Company
Number of share options
Weighted average exercise price
30 June 2024
30 June 2023
30 June 2024
30 June 2023
Number
Number
¬£
¬£
Outstanding at 1 July 2023
4,247,210
219,781
0.0773
0.3997
Granted
2,386,238
4,119,285
0.00
0.07
Forfeited
(918,454)
(86,648)
0.0697
0.4642
Exercised
-
(5,208)
-
0.0025
Outstanding at 30 June 2024
5,714,994
4,247,210
0.0463
0.0773
Exercisable at 30 June 2024
123,757
70,836
0.3230
0.0025
The options outstanding at 30 June 2024 had an exercise price ranging from ¬£0.00 to ¬£0.70 and a remaining contractual life of up to 2 years and 4 months. The options exist at 30 June 2024 across the following share option schemes:
Number of shares
Exercise price per share (¬£)
Fair value of scheme
Vesting period
EMI scheme granted in April 2021
66,668
0.00025
54,880
1 year
SAYE scheme granted in March 2021
57,089
0.70
6,295
3 years
LTIP scheme granted in December 2022
3,204,999
0.07
107,542
3 years
LTIP scheme granted in October 2023
2,386,238
0.00
7,491
3 years
5,714,994
176,208
The fair value of the scheme is being expensed over the vesting period. All share options expire 10 years after the date of issue.
Group
30 June 2024
¬£'000
30 June 2023
¬£'000
Expenses recognised in the year
Arising from equity settled share-based payment transactions
48
28
48
28
9. Acquisition of a business
On the 3rd May 2024 the Group acquired 100% percent of the issued capital of IVDeology Holdings Ltd. In accordance with IFRS 3 Business Combinations, goodwill of ¬£378,923 arising from the acquisition and ¬£104,582 of separable intangibles assets have been recognised.
The total consideration for the acquisition was ¬£700k. Of the total consideration, ¬£500k was made up of share issues granted Abingdon Health plc to the previous shareholders of IVDeology Holdings Ltd as at the date of completion. In addition to this there is a total amount of ¬£200k earn-out consideration similarly to be settled in the issue of share capital in Abingdon Health Plc. The earn-out consideration constitutes employee remuneration and is considered to represent a share-based payment. This consideration is spread across the vesting period and as a result, ¬£16,667 has been expensed as a share-based payment in the Statement of Profit and Loss. This consideration has been excluded from total consideration in the below reconciliation.
The net assets of the business acquired are as follows:
Group
Book value
Adjustments
Fair value
¬£'000
¬£'000
¬£'000
Property, plant and equipment
57
-
57
Intangible Assets
4
104
108
Trade and other Receivables
40
-
40
Cash and Cash equivalents
1
-
1
Trade and other payables
(59)
-
(59)
Deferred tax
-
(26)
(26)
Total identifiable net assets
43
78
121
Goodwill
379
Total consideration
500
10. Events after the reporting date
In August 2024 Abingdon completed the acquisition of Compliance Solutions group which specialises in meeting regulatory requirements of its international client base in the UK IVD and medical device markets.
The Compliance Solutions group's team (currently c.36 employees) provides consultancy services, ranging from preparation of technical files for regulatory approvals, clinical strategy advice and protocol design and regulatory inspection gap analysis; design, implementation and maintenance of quality management systems; technical file and design file reviews, clinical evaluation reports and biological safety evaluations; and internal audit programmes; supplier audits, pre-audit preparations (e.g. FDA, MHRA, Notified Body, unannounced) and mock Notified Body/FDA audits.
In its financial year ending 30 June 2023, the main trading entity Compliance Solutions (Life Sciences) Limited generated turnover of ¬£2,716k; resulting in EBITDA of ¬£393k.
The Compliance Solutions Group's activities are complementary to those of the Group and recently acquired IVDeology; and increase the breadth and depth of the Group's regulatory expertise. Furthermore, there is, in the Board's opinion, the opportunity to cross-sell the Group's services, such as lateral flow development and manufacture and analytical laboratory support, into the Compliance Solutions Group's customer base.
The maximum consideration of ¬£3.2m comprises:
i. cash of ¬£1.36m to be paid as follows: ¬£700,000 on completion and then 3 equal payments of ¬£220k at the end of the first, second and third month following completion; and
ii. the sum of ¬£1.0m to be satisfied by the issue of 9,216,590 Ordinary Shares; and
iii. an amount in cash equal to the amounts received by Compliance Solutions (Life Sciences) Limited in respect of certain aged debtors in the 24-month period from Completion, subject to a maximum amount of ¬£340k; and
iv. subject to achieving certain revenue targets in the period starting on the first anniversary of the acquisition and ending on the second anniversary of the Acquisition, an earn out of up to ¬£0.5m to be satisfied by the issue of such number of further Ordinary Shares.
Due to the proximity of the completion of the acquisition to the signing of the current year financial statements, a purchase price allocation exercise has not yet been carried out in respect of Compliance solutions Group. As such, further detail on the acquisition is not disclosed.
In August 2024, Abingdon Health Plc completed a fundraising that raised gross proceeds of ¬£5.6m as set out below:
¬∑
¬£5m in respect of a placing with various Venture Capital Trusts
¬∑
¬£0.2m in respect of a placing with various other institutional shareholders
¬∑
¬£0.4m in respect of a retail offer
11. Prior period adjustment
A restatement has been made to recognise a dilapidation provision in respect of a lease held under IFRS 16 for property used in trade. There were terms present in the lease from inception that required the property to be returned to the original condition, therefore the provision has been recognised in the prior year at the same value it would have been at 1 July 2022, if recognised at the inception of the lease in 2020.
Management have assessed that of a total dilapidation provision of ¬£100,000, 5% would be in relation to wear and tear, which has been treated as an expense. The remaining proportion of the provision that is in relation to capital outflows has been treated as an addition at the inception of the lease and is depreciated over the term of the lease to 2 November 2026.
Changes to the statement of financial position (Group)
At 1 July 2022
At 30 June 2023
Previously reported
Adjustment
As restated
Previously reported
Adjustment
As restated
¬£'000
¬£'000
¬£'000
¬£'000
¬£'000
¬£'000
Non-current assets
Right of Use assets
166
63
229
130
48
178
Other property, plant & equipment
1,611
-
1,611
1,079
-
1,079
Total property, plant & equipment
1,777
63
1,840
1,209
48
1,257
Non-Current liabilities
Provisions
-
(82)
(82)
-
(85)
(85)
Capital and reserves
Accumulated deficit
(24,106)
(19)
(24,125)
(27,456)
(37)
(27,493)
Changes to the statement of comprehensive income (Group)
At 30 June 2023
Previously reported
Adjustment
As restated
¬£'000
¬£'000
¬£'000
Depreciation
(644)
(15)
(659)
Finance costs
(72)
(3)
(75)
Loss for the financial period
(3,451)
(18)
(3,469)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
FR QKOBKBBDBDKK
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Launch of seaweed-based lateral flow housings</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 75/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Launch of seaweed-based lateral flow housings | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">6th Nov 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">75/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Launch of seaweed-based lateral flow housings</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚ö†Ô∏è CRITICAL: Serious company health concerns - potential distress signal</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Privacy Policy</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
6 Nov 2025 07:00
RNS Number : 3869G
Abingdon Health PLC
06 November 2025
6 November 2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Launch of seaweed-based lateral flow housings
Alternative to standard plastic housings to reduce plastic waste from LFTs
Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces the launch of a seaweed-based alternative housing for its contract development and manufacturing (CDMO) customers for the development and manufacture of lateral flow tests (LFTs).
The Company has agreed an exclusive supply agreement with Wolverhampton based
Symbio Technologies Ltd
("SymbioTex") for the supply of compostable bio-based material derived from red-seaweed which can be used to produce lateral flow cassettes via standard injection moulding techniques. This option will provide an alternative to the standard plastic houses that are currently used and create opportunity for Abingdon customers to significantly reduce their plastic waste.
The Company has developed prototype cassettes in both standard format and in mid-stream urine sample format as is used for pregnancy and fertility testing.
Examples of the Company's seaweed-based housings with, on the left side, a positive (left) and negative (right) test for the plant disease Phytopthora spp from the Company's
Pocket Diagnostic¬Æ
range using blue latex as signal.
And on the right side, positive (left) and negative (right) pregnancy tests using colloidal gold label in seaweed-based housings in mid-stream urine format as used in pregnancy and fertility testing.
Olivia Simpson, Managing Director of
SymbioTex, commented
: "
SymbioTex is delighted to¬†have agreed the exclusive supply¬†of our seaweed-based home compostable biomaterial to¬†Abingdon¬†Health.
It is a truly home compostable, sustainable material that can be used to revolutionise the production of packaging and medical devices currently made from single-use plastic."
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:
"
LFTs are crucial for rapid diagnostic testing with over 2 billion used annually across the globe. However, this generates
greater than 20,000¬†tonnes
of plastic waste. By offering a plastic free rigid cassette in a range of formats, Abingdon Health aims to help our CDMO customers reduce plastic waste without compromising on the functionality of the tests. The use of SymbioTex's material, as well as harnessing the power of renewable natural resources, gives us the practical benefit of using traditional
plastic¬†injection moulding
machinery thereby easing the development pathway".
Enquiries:
Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand,¬†Executive
Chairman
Via Walbrook PR
Tom Hayes, CFO
Zeus (Sole Broker and Nominated Adviser)
Tel:
+44 (0)20 3829 5000
Antonio Bossi / Jacob Walker (Corporate Finance)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or
abingdon@walbrookpr.com
Paul McManus¬†/¬†Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About¬†Abingdon Health plc
Abingdon Health¬†Group¬†is a leading med-tech contract service provider offering its services to an international customer base.
The Group's
CDMO
expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success". Abingdon Analytical Ltd offers performance evaluation for lateral flow and other
in vitro
diagnostic assays from its Doncaster laboratory.
Founded in 2008,¬†Abingdon Health¬†is headquartered in¬†York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's
brochure
outlines the comprehensive support the Group can now provide to its international customers. For more information visit:
www.abingdonhealth.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCFLFFTLLLEIIE
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Trading update</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 85/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Trading update | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">5th Aug 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">85/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Trading update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">üü¢ LOW RISK: Positive signals, minimal concerns</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìä ANALYZE: Determine offer price, arbitrage opportunity if discount</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚ö†Ô∏è CRITICAL: Serious company health concerns - potential distress signal</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Financial Highlights</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
5 Aug 2025 07:00
RNS Number : 9298T
Abingdon Health PLC
05 August 2025
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Trading update
Revenue for FY25 in line with market expectations of ¬£8.6m
Continued strong revenue growth anticipated in FY26
York, U.K. 5 August 2025:
Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid tests and med-tech, provides a trading update for the financial year ended 30 June 2025 ("FY25").
Commercial and Operational Highlights
¬∑
Continued growth of contract development and manufacturing organisation ("CDMO") activities with several large contracts secured during FY25 and post period-end including:
o
Contract win
for¬†US$2m¬†for development of sexually transmitted disease tests running across 2025 and into 2026.
o
Funding award of¬†¬£800,000¬†via UK Research and Innovation alongside a distinguished group of partners to develop
point-of-care rapid diagnostic tests for malaria
.
o
Strategic partnership
s
with Okos Diagnostics to jointly develop and commercialise avian flu (H5N1) lateral flow kits for bovine health and human applications.
o
‚Ç¨2m CDMO
contract win
for companion diagnostic test covering development, scale-up, technical transfer, manufacture and full regulatory approval support with a European biotech company.
o
Additional CDMO
contract win
for development and regulatory approval of a companion diagnostic lateral flow point of care test, with a global pharmaceutical company expected to generate c. US$2.5m revenue over a 24-month period.
¬∑
Expansion of integrated CDMO service offering with:
o
Acquisition
of regulatory service provider Compliance Solutions (Life Sciences) in¬†August 2024¬†for a maximum consideration of up to¬†¬£3.2 million¬†in cash and shares.
o
Opening
of Abingdon Analytical Ltd, analytical services and performance evaluation laboratory, in¬†existing premises in Doncaster¬†in¬†December 2024.
¬∑
Integration of CS Lifesciences well underway and contract wins,
including one for >¬£500k
which has since been extended, underpinning significant growth potential in FY26 and beyond.
¬∑
Opening of US CDMO service site
, including a commercial office and laboratories, in¬†Madison, Wisconsin, which was fully operational by¬†April 2025.
Financial Highlights and Outlook
¬∑
Revenue for FY25 expected to be in line with market expectations of¬†¬£8.6m (FY24:¬†¬£6.1m).
¬∑
Cash at bank and in hand of¬†¬£1.9m¬†(31 December 2024:¬†¬£3.7m;¬†30 June 2024:¬†¬£1.4m).
¬∑
Recent acquisitions (IVDeology and CS Lifesciences) trading in line with management expectations.
¬∑
Investments made in new ventures (Abingdon Analytical Ltd and Abingdon Health USA Inc.) supporting new contract wins.
¬∑
The Board is confident of continued strong revenue growth based on the above contract successes and continues to target a cash-flow positive position in calendar year 2026.
The financial update above is provided subject to finalisation of the Group's results for FY25 which are expected to be published in October 2025. Notice of results will be provided in due course.
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented
: "We are pleased to announce in-line revenues are expected for FY25 and confirm that initial progress in FY26 gives us confidence of
continued strong revenue growth
. The investments and acquisitions the Company made during FY25 have significantly strengthened our full service offering. We are now able to offer a fully comprehensive CDMO service with the increasing importance of a regulatory and performance evaluation skill set in addition to our research and development, scale up and manufacturing expertise. This resonates well with our current and prospective clients as evidenced by recent contract wins."
Enquiries:
Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand,¬†Executive
Chairman
Via Walbrook PR
T
om Hayes, CFO
Zeus (Sole Broker and Nominated Adviser)
Tel:
+44 (0)20 3829 5000
Antonio Bossi / Jacob Walker (Corporate Finance)
Fraser Marshall¬†(Corporate Broking)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or
abingdon@walbrookpr.com
Paul McManus¬†/¬†Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About¬†Abingdon Health plc
Abingdon Health¬†Group¬†is a leading med-tech contract service provider offering its services to an international customer base.
The Group's
CDMO
expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success". Abingdon Analytical Ltd offers performance evaluation for lateral flow and other
in vitro
diagnostic assays from its Doncaster laboratory.
Abingdon's regulatory services companies,
Compliance Solutions (Life Sciences)
and
IVDeology
, provide a broad range of regulatory services to the
in vitro
diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the¬†USA, EU and the¬†UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.
Founded in 2008,¬†Abingdon Health¬†is headquartered in¬†York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's
brochure
outlines the comprehensive support the Group can now provide to its international customers. For more information visit:
www.abingdonhealth.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
TSTSSDESLEISEEA
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìà</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Notice of Results</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ BULLISH</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    FINANCIAL RESULTS: Financial results released | ‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4th Oct 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #10b981;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #10b981;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">FINANCIAL RESULTS: Financial results released</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚ö†Ô∏è CRITICAL: Serious company health concerns - potential distress signal</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Investor Presentation</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
4 Oct 2024 07:00
RNS Number : 9104G
Abingdon Health PLC
04 October 2024
Abingdon Health plc
("Abingdon" or "the Company")
Notice of Results
Investor Presentation
York, U.K. 4 October 2024:
Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO),
announces that it expects to release its preliminary results for the year ended 30 June 2024 on Tuesday 8 October.
Investor Presentation
The Company will provide a live presentation relating to the preliminary results via the Investor Meet Company platform on Tuesday 8 October at 9.30am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Abingdon Health plc via:
https://www.investormeetcompany.com/abingdon-health-plc/register-investor
Investors who already follow Abingdon Health plc on the Investor Meet Company platform will automatically be invited.
Enquiries:
Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Yates,
Chief Executive Officer
Via Walbrook PR
Chris Hand,¬†Non-Executive
Chairman
Zeus Capital (Sole Broker and Nominated Adviser)
Tel:
+44 (0)20 3829 5000
Chris Fielding / Isaac Hooper¬†(Corporate Finance)
Fraser Marshall (Corporate Broking)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or
abingdon@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
Phillip Marriage
+44 (0)7867 984 082
About Abingdon Health plc
Abingdon Health¬†Group is a leading med-tech contract service provider offering its services to an international customer base.
The Company's
CDMO division
offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.¬†Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
Abingdon's regulatory services companies,
Compliance Solutions (Life Sciences)
and
IVDeology
, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.
Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The
Abingdon Simply Test
e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008,¬†Abingdon Health¬†is headquartered in¬†York, England.
For more information visit:
www.abingdonhealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
NORDBBDGRDGDGSX
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Holding(s) in Company</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 100/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    HOLDING DISCLOSURE: Holding disclosed | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4th Nov 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4:58 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">100/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">HOLDING DISCLOSURE: Holding disclosed</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìä ANALYZE: Determine offer price, arbitrage opportunity if discount</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Conversion Period</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">7.20%, 7.20%, 7.20%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
4 Nov 2025 16:58
RNS Number : 1788G
Abingdon Health PLC
04 November 2025
TR-1: S
tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
(to be sent to the relevant issuer
and
to the FCA in Microsoft Word format if possible)
i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached
ii
:
Abingdon Health PLC
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification
(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify)iii:
3. Details of person subject to the notification obligation
iv
Name
Northern Powerhouse Investment Fund
City and country of registered office (if applicable)
England
4. Full name of shareholder(s)
(if different from 3.)
v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
vi
:
31 October 2025
6.
Date on which issuer notified (DD/MM/YYYY):
4 November 2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of
voting rights through
financial instruments(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuer
vii
Resulting situation on the date on which threshold was crossed or reached
7.20%
7.20%
18,071,164
Position of previous notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
viii
A: Voting rights attached to shares
Class/type ofshares
ISIN code (if possible)
Number of voting rights
ix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BLF79J41
18,071,164
7.20%
SUBTOTAL 8. A
18,071,164
7.20%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expirationdate
x
Exercise/Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expirationdate
x
Exercise/Conversion Period
xi
Physical or cash
settlement
xii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
xiii
X
Full
chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv
(please add additional rows as necessary)
Name
xv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10.
In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information
xvi
Place of completion
England
Date of completion
4 November 2025
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
HOLBIBFTMTAMBFA
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-17 ‚Ä¢ CrashDash APEX Engine (Advanced Pattern EXploration)<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
            <div style="margin-top: 12px; padding-top: 12px; border-top: 1px solid #e5e7eb; font-size: 11px; color: #999; line-height: 1.5;">
                <strong>APEX</strong> is a CrashDash AI-powered quantitative intelligence platform that analyzes multi-source market signals using advanced pattern recognition. Designed for professional traders and institutional users, it synthesizes technical, sentiment, and fundamental data into actionable market profiles‚Äîready for seamless integration into workflows.
            </div>
        </div>

    </div>
</body>
</html>